ANNOUNCED ONGOING Drug recall · Reported 9 Nov 2026 · FDA company announcement, classification pending
Eugia Vancomycin Hydrochloride for Injection USP- (Single Dose Vial) recalled
Eugia US is recalling Eugia Vancomycin Hydrochloride for Injection USP- (Single Dose Vial), distributed nationwide in the US. The recall was initiated on 6 Nov 2026 and is listed as ongoing.
Recall details
- Recall number
- FDA-PR-7b6bf89015a0
- Recalling firm
- Eugia US
- Brand
- Eugia
- Classification
- Pending
- Status
- Ongoing
- Recall initiated
- 6 Nov 2026
- Reported
- 9 Nov 2026
- Reason category
- Particulate Matter
- Drug class
- Antibiotics
Timeline
| 6 Nov 2026 | Recall initiated by company | |
| 9 Nov 2026 | Published in enforcement report | +3 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Presence of particulate matter identified as a glass particle inside the vial. November 06,2026 – East Windsor, New Jersey, Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) to the hospital/healthcare facility/user level due to the presence of particulate matter identified as a glass particle inside the vial. Risk Statement: There is a reasonable probability that use of product containing glass particulates can cause serious adverse health consequences such as blockage and clotting in blood vessels, which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism) and cause permanent organ damage or death. Additionally, these particles may cause local vein irritation, inflammatory reaction, aggravation of preexisting infections, and allergic reactions. Greater susceptibility may exist in neonates, infants and patients with compromised organ function. To date, Eugia US LLC has not received any reports of adverse events related to this recall. Vancomycin hydrochloride for injection is a glycopeptide antibacterial indicated in adult and pediatric patients (Neonates and Older) for the treatment of Septicaemia, Infective Endocarditis, Skin and Skin Structure Infections, Bone Infections and Lower Respiratory Tract Infections. The recalled product is packaged in 30 mL vial and packed as 10 (vials) X 10 (Printed cartons) X 01 (Shipper) with NDC code as 55150-471-01. The product can be identi
Product as listed by the company
Eugia Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial)
Where it was distributed
Nationwide
Questions about this recall
Why was it recalled?
Presence of particulate matter identified as a glass particle inside the vial. November 06,2026 – East Windsor, New Jersey, Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) to the hospital/healthcare facility/user level due to the presence of particulate matter identified as a glass particle inside the vial. Risk Statement: There is a reasonable probability that use of product containing glass particulates can cause serious adverse health consequences such as blockage and clotting in blood vessels, which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism) and cause permanent organ damage or death. Additionally, these particles may cause local vein irritation, inflammatory reaction, aggravation of preexisting infections, and allergic reactions. Greater susceptibility may exist in neonates, infants and patients with compromised organ function. To date, Eugia US LLC has not received any reports of adverse events related to this recall. Vancomycin hydrochloride for injection is a glycopeptide antibacterial indicated in adult and pediatric patients (Neonates and Older) for the treatment of Septicaemia, Infective Endocarditis, Skin and Skin Structure Infections, Bone Infections and Lower Respiratory Tract Infections. The recalled product is packaged in 30 mL vial and packed as 10 (vials) X 10 (Printed cartons) X 01 (Shipper) with NDC code as 55150-471-01. The product can be identi
Where was it sold?
Nationwide
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does an unclassified recall mean?
The FDA assigns a class once it has assessed the health risk. Until then the recall is listed without one.
Read the official FDA notice · Source record retrieved 9 Nov 2026. This is a company announcement published by the FDA; the FDA has not yet classified the recall. The record is updated when the classification appears in the Enforcement Report. This page reports the record and gives no medical advice.
More recalls from Eugia US
All 18| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Lidocaine HCl Injection, USP 2%, 40 mg recalled by Eugia USLidolog Kit | Eugia US | Other | Nationwide |
| Drug | CLASS II | Gentamicin Injection, USP, (Pediatric), 20 mg recalled by Eugia USGentamicin | Eugia US | Potency & Assay | Nationwide |
| Drug | CLASS II | Tirofiban Hydrochloride Injection 5 mg recalled by Eugia USTirofiban | Eugia US | Potency & Assay | Nationwide |
| Drug | CLASS II | Tirofiban Hydrochloride Injection 12.5 mg recalled by Eugia USTirofiban | Eugia US | Potency & Assay | Nationwide |
| Drug | CLASS II | Testosterone Cypionate Injection, USP, CIII, 200mg per mL recalledTestosterone Cypionate | Eugia US | Manufacturing (CGMP) Deviations | Nationwide |